Études sur les résultats cliniques et le profil de résistance aux antiviraux des personnes infectées par le VIH de type 1, VHB et VHC
Study sites:
AIDS and Hepatitis Clinics in Yaoundé and Douala, Cameroon
Enrolment:
May 2017
Objectives:
HIV, HBV and HCV are blood borne pathogens that are transmitted sexually and vertically causing a high global disease burden. Co-infection of two or three of these viruses is not uncommon in Cameroon since mono-infection rate of HIV is 4.3%, HBV is 8% and HCV is less than 5%. As new antivirals are being introduced in clinics in Cameroon, we do not fully understand the clinical outcome of patients taking these new drug regimens.
We propose to (i) determine the profile of mutations of HIV-1, HBV and HCV associated to drug resistance in mono-infected or co-infected, treatment-naive or treatment-exposed patients and clinical outcome; (ii) determine the association of HLA and KIR genes in the differential outcome of hepatitis B and hepatitis C; (iii) train young scientists on HIV-1, HBV, HCV, HLA and KIR full-length typing by Sanger sequencing and bioinformatics.
Sample size:
210
The CIRCB AIDS and Viral Hepatitis Co-infection Study Group (AViHep)
The mission of this Study Group is to provide a forum with multidisciplinary activities and knowledge on clinical outcome of patients with AIDS & Hepatitis B, and AIDS & hepatitis C, which could be useful for decision making on diagnosis, treatment and vaccine development.
Funding sources:
CIRCB, The CHAIN Project, University of Oxford (Africa Oxford Initiative 2016 (AfOx
Objectifs:
Le VIH, le VHB et le VHC sont des pathogènes transmissibles par le sang qui sont transmis sexuellement et verticalement, ce qui entraîne une charge de morbidité mondiale élevée. La co-infection de deux ou trois de ces virus n’est pas rare au Cameroun puisque le taux de mono-infection du VIH est de 4,3%, le VHB de 8% et le VHC de moins de 5%. Comme de nouveaux antiviraux sont introduits dans les cliniques au Cameroun, nous ne comprenons pas complètement les résultats cliniques des patients prenant ces nouveaux schémas thérapeutiques.